Perspective Therapeutics announces the selection of investigational product (212Pb)VMT-alpha-NET for the treatment of certain patients with neuroendocrine tumors by the U.S. Food and Drug Administration, FDA, to participate in the Chemistry, Manufacturing, and Controls, CMC, Development and Readiness Pilot, CDRP, program. “Our priority is to expeditiously investigate whether (212Pb)VMT-alpha-NET can benefit patients beyond current standard of care in NETs, and if so, be ready to supply patients,” said Thijs Spoor, Perspective Therapeutics’ CEO. “We are grateful to be able to partner with the FDA to that end, and look forward to increased interactions with the FDA on manufacturing readiness.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
- Perspective Therapeutics price target raised to $1.70 from $1.20 at B. Riley
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences
- Perspective Therapeutics price target raised to $1.50 from $1.20 at Oppenheimer
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results